MedPath

Nuvectis Pharma

Nuvectis Pharma logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
13
Market Cap
$130M
Website
http://nuvectis.com
Introduction

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2023-05-24
Last Posted Date
2025-02-13
Lead Sponsor
Nuvectis Pharma, Inc.
Target Recruit Count
40
Registration Number
NCT05873686
Locations
🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

🇺🇸

Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

and more 3 locations

A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
ARID1A Gene Mutation
Ovarian Clear Cell Tumor
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Cancer
Ovarian Clear Cell Carcinoma
Ovarian Endometrioid Tumor
Interventions
First Posted Date
2022-02-07
Last Posted Date
2025-03-18
Lead Sponsor
Nuvectis Pharma, Inc.
Target Recruit Count
61
Registration Number
NCT05226507
Locations
🇺🇸

Honor Health, Phoenix, Arizona, United States

🇺🇸

UC San Diego Health - Moores Cancer Center, La Jolla, California, United States

🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

and more 20 locations

News

Nuvectis Pharma to Present Promising NXP900 Data at 2025 AACR Meeting

Nuvectis Pharma will showcase five presentations on their novel SRC/YES1 inhibitor NXP900 at the 2025 AACR Meeting in Chicago from April 25-30, highlighting its potential in multiple cancer types.

Nuvectis Pharma's NXP800 Shows Promise in ARID1a-Mutated Ovarian Cancer Trial

Nuvectis Pharma's NXP800 demonstrates antitumor activity in a Phase 1b study for ARID1a-mutated ovarian cancer resistant to platinum-based chemotherapy.

Nuvectis Pharma Reports Financial Results and Highlights Clinical Progress of NXP800 and NXP900

Nuvectis Pharma reported a net loss of $4.2 million for the quarter ended September 30, 2024, a decrease of $1.7 million compared to the same period in 2023.

© Copyright 2025. All Rights Reserved by MedPath